Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...

When Jeanne began to seriously consider taking Zepbound, one of the new-generation weight-loss drugs, she had the briefest of ...

Lange explained on a conference call that one reason for the miss was a flexible treatment protocol that allowed patients to scale down their dosing if, for example, they experienced side effects like ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

The study lasts up to five weeks and involves four to five visits to the Center for Human Nutrition. The study involves measuring body composition, sleep, mood, diet and other aspects of health.

Novo Nordisk NVO is scheduled to report fourth-quarter 2024 results on Feb. 5, 2025, before the opening bell. The Zacks ...

Drugmakers have poured small fortunes into the development of weight loss medicines in the past few years in attempts to lead ...

The results of the first head-to-head trial of Lilly's dual GLP-1/GIP agonist Zepbound (tirzepatide ... achieved a 20.2% reduction in weight at 72 weeks, compared to 13.7% with the maximum ...

On average, Zepbound led to a superior weight loss of 20.2% compared to 13.7% with Wegovy.i At 72 weeks, Zepbound beat Wegovy on both the primary endpoint and all five key secondary endpoints in ...

Pharma giant Novo Nordisk, the company behind Wegovy and Ozempic, expects to launch six products in the next five years. Leading the pack of new drugs will be CagriSema.

Novo Nordisk has a dominant position in diabetes and weight-loss drugs, strong financial growth outlook, and great potential. Click to read why NVO is a Strong Buy.